Table 4.
Correlation of clinical factors for high-risk of fracture in FRAX with and without BMD and osteoporosis by the WHO criteria among patients with systemic lupus erythematosus.
| Variable | High-risk in FRAX with BMD (r, P-value) | High-risk in FRAX without BMD (r, P-value) | Osteoporosis by the WHO criteria (r, P-value) |
|---|---|---|---|
| Oral ulcer | −0.01, 0.88 | −0.01, 0.87 | −0.07, 0.42 |
| Arthritis | 0.12, 0.14 | 0.14, 0.08 | 0.01, 0.98 |
| Hematologic manifestation | −0.09, 0.28 | 0.05, 0.51 | 0.17, 0.04∗ |
| Serositis | −0.01, 0.88 | 0.05, 0.57 | −0.06, 0.58 |
| Nephritis | −0.12, 0.15 | −0.06, 0.47 | −0.07, 0.42 |
| SLEDAI | −0.04, 0.6 | 0.01, 0.91 | −0.06, 0.44 |
| Low complement level | −0.06, 0.5 | −0.12, 0.13 | 0.26, 0.001∗ |
| ESR | 0.13, 0.12 | 0.08, 0.35 | 0.27, 0.001∗ |
| Glucocorticoid cumulative dose | 0.3, < 0.001∗ | 0.21, 0.008∗ | 0.16, 0.05 |
FRAX, fracture risk assessment tool; BMD, bone mineral density; WHO, World Health Organization; SLEDAI, systemic lupus erythematosus disease activity index; ESR: erythrocyte sedimentation rate.